Foxglove is seeking a Senior UK Policy and Advocacy Consultant to support our legislative advocacy and development of proactive policy positions across both strands of our work. Reporting to Director Cori Crider, the consultant will track prospective legislative and policy changes which could impact Foxglove's work. They will engage their existing networks of policymakers, politicians, civil society groups, lawyers and experts and help Foxglove build and maintain new relationships. The postholder will prepare written materials and suggested amendments, build and support coalitions, advocate for amendments and meet decisionmakers on Foxglove issues.

This role will help us design and intervene on several potential policy/legislative areas, with an initial focus on the Digital Markets, Competition and Consumers Bill. This draft legislation would give a suite of powers to the UK's Competition Regulator and will set standards for review of the regulator's decisions, particularly its Digital Markets Unit.

Foxglove is seeking consultant support concerning two policy positions - one defending the 'judicial review' standard for challenging Competition Markets Authority (CMA) decisions and another to improve the draft legislation by adding provisions to better assist public interest litigants to participate in enforcement challenges.

We also anticipate the postholder supporting our work to reform NHS patient consent mechanisms, such as the National Data Opt-Out.

There have been multiple government efforts to centralise NHS health data - from the National Programme for IT, care.data, to 2021's GP data scheme, GPDPR. These efforts failed because of patient distrust and mass patient opt-outs. The latest such effort, the Federated Data Platform (FDP), for GBP320 million, risks a similar crisis of trust in patient control over their health record.

We believe that given the choice, most patients would support secondary uses of their health data, for research and planning for example, to benefit their care and the NHS. But we also believe legitimate concerns over commercial access drive mass opt-outs, and that an overhaul of patient choice is necessary - not just to give patients control, but as the only realistic way of getting the millions of people who have opted out of data sharing to opt back in. A second area of focus would potentially involve helping us scope and advocate for a programme of choice reform.

Please see attached Job Description which includes instructions on how to apply.